Drug manufacturer Eli Lilly (NYSE:LLY) announced today that Revenue in the fourth quarter rose 45% to $13.53 billion, driven by volume growth from Mounjaro and Zepbound, versus the consensus of $13.78 billion.

The company said it expects to report 2025 income per share of $22.50 to $24.00 in 2025, compared with analysts’ estimates of $22.86 per share. It added that it anticipates results will be partially driven by the launch of its Mounjaro diabetes medicine in additional worldwide markets.

“We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth,” said Lilly CEO David Ricks in a statement.

This better-than-expected outlook comes after the group’s previously unveiled quarterly sales for its obesity medications last month that came up short of analysts’ forecasts, due in part to constraints at wholesalers. Sales of Mounjaro were $3.53 billion, missing projections of $4.27 billion. Meanwhile, its Zepbound weight-loss drug grew by 52% against the previous quarter to $1.91 billion, also below expectations.

Eli Lilly’s stock rose on the news, and at 10.59AM ET it was up 3.2%.